---
title: "Needham maintains Buy rating on NeoGenomics, $22 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301026983.md"
description: "Needham maintained a Buy rating on NeoGenomics with a $22 price target, implying 15% upside. The firm cited strong Q3 revenue growth of 11% YoY to $209 million and robust NGS revenue forecasts. Additionally, the appointment of Warren Stone as new CEO effective January 2027 signals leadership stabilization, supporting continued success in cancer diagnostics."
datetime: "2026-10-06T11:12:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301026983.md)
  - [en](https://longbridge.com/en/news/301026983.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301026983.md)
generator: "portal-rs"
---

# Needham maintains Buy rating on NeoGenomics, $22 price target

Needham maintained their Buy rating on NeoGenomics's stock with a price target of $22.00.

The price target implies an upside of 15.0% from the Oct 5 close of $19.13.

**Key takeaways from the analyst note**

**Strong Revenue Growth**: NeoGenomics demonstrated impressive revenue growth, with a 3Q26 revenue of $209 million, representing an 11% year-over-year increase, which exceeded consensus expectations. This momentum is supported by a robust growth forecast for next-generation sequencing (NGS) revenue, projected to grow approximately 28% year-over-year.

**Strategic Leadership Transition**: The announcement of Warren Stone as the new CEO, effective January 2027, signals a potential stabilization in leadership after a period of frequent changes. Stone's prior experience and the company's strong operational guidance suggest that NeoGenomics is positioned for continued success and market share expansion in the cancer diagnostics sector.

Explore more price target data and ratings for NeoGenomics on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [NEO.US](https://longbridge.com/en/quote/NEO.US.md)

## Related News & Research

- [NeoGenomics Q3 revenue beats estimates on higher-value cancer testing; raises FY2026 outlook](https://longbridge.com/en/news/303450077.md)
- [StoneX maintains Buy rating on NeoGenomics, $20 price target](https://longbridge.com/en/news/301036979.md)
- [Palantir Q3 Earnings Preview: Revenue Expected to Grow 84% Above High End of Company Guidance, Highest Wall Street Target Reaches $265](https://longbridge.com/en/news/303921433.md)
- [Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop?](https://longbridge.com/en/news/303867113.md)
- [3,292 UnitedHealth Group Incorporated $UNH Shares Sold by Heritage Investors Management Corp](https://longbridge.com/en/news/303948988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**